Search
moxetumomab pasudotox (Lumoxiti)
Indications:
- treatment of hairy cell leukemia in patients who have failed >=2 previous treatments
Adverse effects:
boxed warning
- risk of hemolytic uremic syndrome & capillary leak syndrome
Mechanism of action:
- anti-CD22 monoclonal antibody
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
antineoplastic monoclonal antibody
References
- Ingram I.
Lumoxiti OK'd for Hairy Cell Leukemia - FDA approval marks
first anti-CD22 drug for treating the rare disease.
MedPage Today. Sept. 13, 2018
https://www.medpagetoday.com/hematologyoncology/leukemia/75087
- FDA News Release. September 13, 2018
FDA approves new kind of treatment for hairy cell leukemia.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm620448.htm